Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic breast cancer in the European Union. The cobas PIK3CA mutation test, performed in the lab (in vitro) and previously available for research purposes only, is now available in countries accepting the CE mark. “We are pleased to offer the cobas PIK3CA Mutation Test […], enabling clinicians to accurately and quickly manage their breast cancer patients,” Thomas Schinecker,…
You must be logged in to read/download the full post.
The post Genetic Test for Advanced Breast Cancer Launched in EU appeared first on BioNewsFeeds.